[1]
|
Loibl, S., Poortmans, P., Morrow, M., Denkert, C. and Curigliano, G. (2021) Breast Cancer. Lancet, 397, 1750-1769. https://doi.org/10.1016/S0140-6736(20)32381-3
|
[2]
|
Dan, V.M., Raveendran, R.S. and Baby, S. (2021) Resistance to Intervention: Paclitaxel in Breast Cancer. Mini-Reviews in Medicinal Chemistry, 21, 1237-1268. https://doi.org/10.2174/1389557520999201214234421
|
[3]
|
Lin, W., Zhou, Q., Wang, C.Q., Zhu, L., Bi, C., Zhang, S., Wang, X. and Jin, H. (2020) lncRNAs Regulate Metabolism in Cancer. International Journal of Biological Sciences, 16, 1194-1206. https://doi.org/10.7150/ijbs.40769
|
[4]
|
Qian, X., Zhao, J., Yeung, P.Y., Zhang, Q.C. and Kwok, C.K. (2019) Revealing lncRNA Structures and Interactions by Sequencing-Based Approaches. Trends in Biochemical Sciences, 44, 33-52. https://doi.org/10.1016/j.tibs.2018.09.012
|
[5]
|
Peng, L., Jiang, J., Tang, B., Nice, E.C., Zhang, Y.Y. and Xie, N. (2020) Managing Therapeutic Resistance in Breast Cancer: From the lncRNAs Perspective. Theranostics, 10, 10360-10377. https://doi.org/10.7150/thno.49922
|
[6]
|
Zhang, X. and Yang, H. (2020) Research Progress on Long Non-Coding RNAs and Drug Resistance of Breast Cancer. Clinical Breast Cancer, 20, 275-282. https://doi.org/10.1016/j.clbc.2019.11.001
|
[7]
|
Zeng, Y., Wang, G., Zhou, C.F., Zhang, H.B., Sun, H., Zhang, W., Zhou, H.H., Liu, R. and Zhu, Y.S. (2019) lncRNA Profile Study Reveals a Three-lncRNA Signature Associated with the Pathological Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer. Frontiers in Pharmacology, 10, Article 574. https://doi.org/10.3389/fphar.2019.00574
|
[8]
|
Pan, Y., Pan, Y., Cheng, Y., Yang, F., Yao, Z. and Wang, O. (2018) Knockdown of lncRNA MAPT-AS1 Inhibites Proliferation and Migration and Sensitizes Cancer Cells to Paclitaxel by Regulating MAPT Expression in ER-Negative Breast Cancers. Cell & Bioscience, 8, Article No. 7. https://doi.org/10.1186/s13578-018-0207-5
|
[9]
|
Wang, R., Zhang, T., Yang, Z., Jiang, C. and Seng, J. (2018) Long Non-Coding RNA FTH1P3 Activates Paclitaxel Resistance in Breast Cancer through MiR-206/ABCB1. Journal of Cellular and Molecular Medicine, 22, 4068-4075. https://doi.org/10.1111/jcmm.13679
|
[10]
|
Chang, L., Hu, Z., Zhou, Z. and Zhang, H. (2018) Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer. Cellular Physiology and Biochemistry, 48, 16-28. https://doi.org/10.1159/000491659
|
[11]
|
Li, Y., Wang, Y., Wang, H., Zhang, L., Ding, Y., Chen, S., Yang, Q. and Chen, C. (2017) [Effects of lncRNA RP11-770J1.3 and TMEM25 Expression on Paclitaxel Resistance in Human Breast Cancer Cells]. Journal of Zhejiang University, 46, 364-370.
|
[12]
|
Zheng, S., Fu, W., Huang, Q., Zhou, J., Lu, K., Gu, J., Ma, R. and Guo, G. (2023) lncRNA PRKCQ-AS1 Regulates Paclitaxel Resistance in Triple-Negative Breast Cancer Cells Through MiR-361-5p/PIK3C3 Mediated Autophagy. Clinical and Experimental Pharmacology and Physiology, 50, 431-442. https://doi.org/10.1111/1440-1681.13758
|
[13]
|
Zhang, H., Zhao, B., Wang, X., Zhang, F. and Yu, W. (2019) LINC00511 Knockdown Enhances Paclitaxel Cytotoxicity in Breast Cancer via Regulating MiR-29c/CDK6 Axis. Life Sciences, 228, 135-144. https://doi.org/10.1016/j.lfs.2019.04.063
|
[14]
|
Zheng, P., Dong, L., Zhang, B., Dai, J., Zhang, Y., Wang, Y. and Qin, S. (2019) Long Noncoding RNA CASC2 Promotes Paclitaxel Resistance in Breast Cancer through Regulation of MiR-18a-5p/CDK19. Histochemistry and Cell Biology, 152, 281-291. https://doi.org/10.1007/s00418-019-01794-4
|
[15]
|
Liu, C., Jiang, F., Zhang, X. and Xu, X. (2020) Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via MiR-613/CDK12 Axis. Cancer Management and Research, 12, 2777-2788. https://doi.org/10.2147/CMAR.S241969
|
[16]
|
Shin, V.Y., Chen, J., Cheuk, I.W., Siu, M.T., Ho, C.W., Wang, X., Jin, H. and Kwong, A. (2019) Long Non-Coding RNA NEAT1 Confers Oncogenic Role in Triple-Negative Breast Cancer through Modulating Chemoresistance and Cancer Stemness. Cell Death & Disease, 10, Article No. 270. https://doi.org/10.1038/s41419-019-1513-5
|
[17]
|
Gu, M., Zheng, W., Zhang, M., Dong, X., Zhao, Y., Wang, S., Jiang, H. and Zheng, X. (2020) lncRNA NONHSAT141924 Promotes Paclitaxel Chemotherapy Resistance through P-CREB/Bcl-2 Apoptosis Signaling Pathway in Breast Cancer. Journal of Cancer, 11, 3645-3654. https://doi.org/10.7150/jca.39463
|
[18]
|
Si, X., Zang, R., Zhang, E., Liu, Y., Shi, X., Zhang, E., Shao, L., Li, A., Yang, N., Han, X., et al. (2016) lncRNA H19 Confers Chemoresistance in ERalpha-Positive Breast Cancer through Epigenetic Silencing of the Pro-Apoptotic Gene BIK. Oncotarget, 7, 81452-81462. https://doi.org/10.18632/oncotarget.13263
|
[19]
|
Li, P.P., Li, R.G., Huang, Y.Q., Lu, J.P., Zhang, W.J. and Wang, Z.Y. (2021) lncRNA OTUD6B-AS1 Promotes Paclitaxel Resistance in Triple Negative Breast Cancer by Regulation of MiR-26a-5p/MTDH Pathway-Mediated Autophagy and Genomic Instability. Aging, 13, 24171-24191. https://doi.org/10.18632/aging.203672
|
[20]
|
Zhao, T., Zhang, T., Zhang, Y., Zhou, B. and Lu, X. (2022) Paclitaxel Resistance Modulated by the Interaction between TRPS1 and AF178030.2 in Triple-Negative Breast Cancer. Evidence-Based Complementary and Alternative Medicine, 2022, Article ID: 6019975. https://doi.org/10.1155/2022/6019975
|
[21]
|
Gligorov, J. and Lotz, J.P. (2004) Preclinical Pharmacology of the Taxanes: Implications of the Differences. Oncologist, 9, 3-8. https://doi.org/10.1634/theoncologist.9-suppl_2-3
|
[22]
|
Huang, P., Li, F., Li, L., You, Y., Luo, S., Dong, Z., Gao, Q., Wu, S., Brunner, N. and Stenvang, J. (2018) lncRNA Profile Study Reveals the MRNAs and lncRNAs Associated with Docetaxel Resistance in Breast Cancer Cells. Scientific Reports, 8, Article No. 17970. https://doi.org/10.1038/s41598-018-36231-4
|
[23]
|
Li, J., Ke, J., Qin, C.L. and Zhu, X. (2022) LINC00680 Modulates Docetaxel Resistance in Breast Cancer via the MiR-320b/CDKL5 Axis. International Journal of Immunopathology and Pharmacology, 36, 1-9. https://doi.org/10.1177/03946320221105608
|
[24]
|
Li, J., Kang, J., Liu, W., Liu, J., Pan, G., Mao, A., Zhang, Q., Lu, J., Ding, J. and Li, H. (2022) Docetaxel-Resistant Triple-Negative Breast Cancer Cell-Derived Exosomal lncRNA LINC00667 Reduces the Chemosensitivity of Breast Cancer Cells to Docetaxel via Targeting MiR-200b-3p/Bcl-2 Axis. European Journal of Histochemistry, 66, 3592. https://doi.org/10.4081/ejh.2022.3529
|
[25]
|
Zhang, C., Wang, J., Zhang, J., Qu, H. and Tang, X. (2020) LINC00461 Overexpression Can Induce Docetaxel Resistance in Breast Cancer by Interacting with MiR-411-5p. OncoTargets and Therapy, 13, 5551-5562. https://doi.org/10.2147/OTT.S247776
|
[26]
|
Ning, X., Zhao, J., He, F., Yuan, Y., Li, B. and Ruan, J. (2021) Long Non-Coding RNA TMPO-AS1 Facilitates Chemoresistance and Invasion in Breast Cancer by Modulating the MiR-1179/TRIM37 Axis. Oncology Letters, 22, Article No. 500. https://doi.org/10.3892/ol.2021.12761
|
[27]
|
Zhang, Z., Yu, X., Yu, X., Wang, Z., Wu, P. and Huang, J. (2015) Anthracyclines Potentiate Anti-Tumor Immunity: A New Opportunity for Chemoimmunotherapy. Cancer Letters, 369, 331-335. https://doi.org/10.1016/j.canlet.2015.10.002
|
[28]
|
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. and Gianni, L. (2004) Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacological Reviews, 56, 185-229. https://doi.org/10.1124/pr.56.2.6
|
[29]
|
Yao, N., Fu, Y., Chen, L., Liu, Z., He, J., Zhu, Y., et al. (2019) Long Non-Coding RNA NONHSAT101069 Promotes Epirubicin Resistance, Migration, and Invasion of Breast Cancer Cells through NONHSAT101069/MiR-129-5p/Twist1 Axis. Oncogene, 38, 7216-7233. https://doi.org/10.1038/s41388-019-0904-5
|
[30]
|
Gooding, A.J., Zhang, B., Gunawardane, L., Beard, A., Valadkhan, S. and Schiemann, W.P. (2019) The lncRNA BORG Facilitates the Survival and Chemoresistance of Triple-Negative Breast Cancers. Oncogene, 38, 2020-2041. https://doi.org/10.1038/s41388-018-0586-4
|
[31]
|
Chen, Z., Pan, T., Jiang, D., Jin, L., Geng, Y., Feng, X., et al. (2020) The lncRNA-GAS5/MiR-221-3p/DKK2 Axis Modulates ABCB1-Mediated Adriamycin Resistance of Breast Cancer via the Wnt/β-Catenin Signaling Pathway. Nucleic Acids, 19, 1434-1448. https://doi.org/10.1016/j.omtn.2020.01.030
|
[32]
|
He, D.X., Zhang, G.Y., Gu, X.T., Mao, A.Q., Lu, C.X., Jin, J., Liu, D.Q. and Ma, X. (2016) Genome-Wide Profiling of Long Non-Coding RNA Expression Patterns in Anthracycline-Resistant Breast Cancer Cells. International Journal of Oncology, 49, 1695-1703. https://doi.org/10.3892/ijo.2016.3665
|
[33]
|
O’Brien, K.M., Cole, S.R., Tse, C.K., Perou, C.M., Carey, L.A., Foulkes, W.D., Dressler, L.G., Geradts, J. and Millikan, R.C. (2010) Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study. Clinical Cancer Research, 16, 6100-6110. https://doi.org/10.1158/1078-0432.CCR-10-1533
|
[34]
|
Adriaens, C., Standaert, L., Barra, J., Latil, M., Verfaillie, A., Kalev, P., Boeckx, B., Wijnhovwn, P.W., Radaelli, E., Vwemi, W., et al. (2016) P53 Induces Formation of NEAT1 lncRNA-Containing Paraspeckles That Modulate Replication Stress Response and Chemosensitivity. Nature Medicine, 22, 861-868. https://doi.org/10.1038/nm.4135
|
[35]
|
Zhang, M., Yang, L., Hou, L. and Tang, X. (2021) lncRNA SNHG1 Promotes Tumor Progression and Cisplatin Resistance through Epigenetically Silencing MiR-381 in Breast Cancer. Bioengineered, 12, 9239-9250. https://doi.org/10.1080/21655979.2021.1996305
|
[36]
|
Du, C., Wang, Y., Zhang, Y., Zhang, J., Zhang, L. and Li, J. (2020) lncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-Negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis. Cell Transplantation, 29, 1-11. https://doi.org/10.1177/0963689720929983
|
[37]
|
Wu, J., Chen, H., Ye, M., Wang, B., Zhang, Y., Sheng, J., Meng, T. and Chen, H. (2019) Long Noncoding RNA HCP5 Contributes to Cisplatin Resistance in Human Triple-Negative Breast Cancer via Regulation of PTEN Expression. Biomedicine & Pharmacotherapy, 115, Article ID: 108869. https://doi.org/10.1016/j.biopha.2019.108869
|